BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
95.87-1.53 (-1.57%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close97.40
Bid94.50 x 100
Ask98.48 x 100
Day's Range95.43 - 97.49
52wk Range62.12 - 118.48
1y Target EstN/A
Market Cap16.37B
P/E Ratio (ttm)-29.17
Avg Vol (3m)1,820,830
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Investopedia8 hours ago

    BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)

    Following its loss in a U.S. patent infringement ruling, BioMarin is taking further steps agains rival Sarepta

  • Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
    Insider Monkey4 days ago

    Blue Jay Capital Betting On Big Returns From These Healthcare Stocks

    Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California. Prior to founding Blue Jay Capital (named after Canada’s only current Major League Baseball team, the Toronto Blue Jays), Mr. Sinclair founded and ran another healthcare-focused hedge fund Expo Capital Management (named after the former Canadian MLB team the Montreal […]

  • TheStreet.com5 days ago

    Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling

    BioMarin (BMRN) announced today that it would seek further review of a Patent Trial and Appeal Board ruling over Sarepta's (SRPT) Duchenne muscular dystrophy drug.